359 related articles for article (PubMed ID: 29577894)
1. Bilateral quinolinic acid-induced lipid peroxidation, decreased striatal monoamine levels and neurobehavioral deficits are ameliorated by GIP receptor agonist D-Ala
Verma MK; Goel R; Nandakumar K; Nemmani KVS
Eur J Pharmacol; 2018 Jun; 828():31-41. PubMed ID: 29577894
[TBL] [Abstract][Full Text] [Related]
2. Effect of D-Ala
Verma MK; Goel R; Nandakumar K; Nemmani KVS
Eur J Pharmacol; 2017 Jun; 804():38-45. PubMed ID: 28366809
[TBL] [Abstract][Full Text] [Related]
3. Sertraline and venlafaxine improves motor performance and neurobehavioral deficit in quinolinic acid induced Huntington's like symptoms in rats: Possible neurotransmitters modulation.
Gill JS; Jamwal S; Kumar P; Deshmukh R
Pharmacol Rep; 2017 Apr; 69(2):306-313. PubMed ID: 28178592
[TBL] [Abstract][Full Text] [Related]
4. Protective Effect of Spermidine Against Excitotoxic Neuronal Death Induced by Quinolinic Acid in Rats: Possible Neurotransmitters and Neuroinflammatory Mechanism.
Jamwal S; Singh S; Kaur N; Kumar P
Neurotox Res; 2015 Aug; 28(2):171-84. PubMed ID: 26078029
[TBL] [Abstract][Full Text] [Related]
5. Probucol modulates oxidative stress and excitotoxicity in Huntington's disease models in vitro.
Colle D; Hartwig JM; Soares FA; Farina M
Brain Res Bull; 2012 Mar; 87(4-5):397-405. PubMed ID: 22245028
[TBL] [Abstract][Full Text] [Related]
6. Blockade of quinolinic acid-induced neurotoxicity by pyruvate is associated with inhibition of glial activation in a model of Huntington's disease.
Ryu JK; Kim SU; McLarnon JG
Exp Neurol; 2004 May; 187(1):150-9. PubMed ID: 15081596
[TBL] [Abstract][Full Text] [Related]
7. Minocycline modulates neuroprotective effect of hesperidin against quinolinic acid induced Huntington's disease like symptoms in rats: behavioral, biochemical, cellular and histological evidences.
Kumar A; Chaudhary T; Mishra J
Eur J Pharmacol; 2013 Nov; 720(1-3):16-28. PubMed ID: 24211676
[TBL] [Abstract][Full Text] [Related]
8. Protective effect of montelukast against quinolinic acid/malonic acid induced neurotoxicity: possible behavioral, biochemical, mitochondrial and tumor necrosis factor-α level alterations in rats.
Kalonia H; Kumar P; Kumar A; Nehru B
Neuroscience; 2010 Nov; 171(1):284-99. PubMed ID: 20813166
[TBL] [Abstract][Full Text] [Related]
9. Suppressing inflammatory cascade by cyclo-oxygenase inhibitors attenuates quinolinic acid induced Huntington's disease-like alterations in rats.
Kalonia H; Kumar A
Life Sci; 2011 Apr; 88(17-18):784-91. PubMed ID: 21362433
[TBL] [Abstract][Full Text] [Related]
10. Correlations between behavioural and oxidative parameters in a rat quinolinic acid model of Huntington's disease: protective effect of melatonin.
Antunes Wilhelm E; Ricardo Jesse C; Folharini Bortolatto C; Wayne Nogueira C
Eur J Pharmacol; 2013 Feb; 701(1-3):65-72. PubMed ID: 23340221
[TBL] [Abstract][Full Text] [Related]
11. Adenosine A2A receptor blockade before striatal excitotoxic lesions prevents long term behavioural disturbances in the quinolinic rat model of Huntington's disease.
Scattoni ML; Valanzano A; Pezzola A; March ZD; Fusco FR; Popoli P; Calamandrei G
Behav Brain Res; 2007 Jan; 176(2):216-21. PubMed ID: 17123640
[TBL] [Abstract][Full Text] [Related]
12. Neuroprotective effect of MK-801 against intra-striatal quinolinic acid induced behavioral, oxidative stress and cellular alterations in rats.
Kalonia H; Kumar P; Nehru B; Kumar A
Indian J Exp Biol; 2009 Nov; 47(11):880-92. PubMed ID: 20099461
[TBL] [Abstract][Full Text] [Related]
13. Excitotoxic brain damage involves early peroxynitrite formation in a model of Huntington's disease in rats: protective role of iron porphyrinate 5,10,15,20-tetrakis (4-sulfonatophenyl)porphyrinate iron (III).
Pérez-De La Cruz V; González-Cortés C; Galván-Arzate S; Medina-Campos ON; Pérez-Severiano F; Ali SF; Pedraza-Chaverrí J; Santamaría A
Neuroscience; 2005; 135(2):463-74. PubMed ID: 16111817
[TBL] [Abstract][Full Text] [Related]
14. Neuroprotective Activity of Curcumin in Combination with Piperine against Quinolinic Acid Induced Neurodegeneration in Rats.
Singh S; Kumar P
Pharmacology; 2016; 97(3-4):151-60. PubMed ID: 26828892
[TBL] [Abstract][Full Text] [Related]
15. Blockade of striatal adenosine A2A receptor reduces, through a presynaptic mechanism, quinolinic acid-induced excitotoxicity: possible relevance to neuroprotective interventions in neurodegenerative diseases of the striatum.
Popoli P; Pintor A; Domenici MR; Frank C; Tebano MT; Pèzzola A; Scarchilli L; Quarta D; Reggio R; Malchiodi-Albedi F; Falchi M; Massotti M
J Neurosci; 2002 Mar; 22(5):1967-75. PubMed ID: 11880527
[TBL] [Abstract][Full Text] [Related]
16. Glial cell line-derived neurotrophic factor attenuates the excitotoxin-induced behavioral and neurochemical deficits in a rodent model of Huntington's disease.
Araujo DM; Hilt DC
Neuroscience; 1997 Dec; 81(4):1099-110. PubMed ID: 9330371
[TBL] [Abstract][Full Text] [Related]
17. Improvement of mitochondrial NAD(+)/FAD(+)-linked state-3 respiration by caffeine attenuates quinolinic acid induced motor impairment in rats: implications in Huntington's disease.
Mishra J; Kumar A
Pharmacol Rep; 2014 Dec; 66(6):1148-55. PubMed ID: 25443748
[TBL] [Abstract][Full Text] [Related]
18. Neuroprotective effect of naringin, a flavone glycoside in quinolinic acid-induced neurotoxicity: Possible role of PPAR-γ, Bax/Bcl-2, and caspase-3.
Cui J; Wang G; Kandhare AD; Mukherjee-Kandhare AA; Bodhankar SL
Food Chem Toxicol; 2018 Nov; 121():95-108. PubMed ID: 30130594
[TBL] [Abstract][Full Text] [Related]
19. Neuroprotective effects of roflumilast against quinolinic acid-induced rat model of Huntington's disease through inhibition of NF-κB mediated neuroinflammatory markers and activation of cAMP/CREB/BDNF signaling pathway.
Saroj P; Bansal Y; Singh R; Akhtar A; Sodhi RK; Bishnoi M; Sah SP; Kuhad A
Inflammopharmacology; 2021 Apr; 29(2):499-511. PubMed ID: 33517508
[TBL] [Abstract][Full Text] [Related]
20. Licofelone attenuates quinolinic acid induced Huntington like symptoms: possible behavioral, biochemical and cellular alterations.
Kalonia H; Kumar P; Kumar A
Prog Neuropsychopharmacol Biol Psychiatry; 2011 Mar; 35(2):607-15. PubMed ID: 21237233
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
